Compare NTIC & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTIC | ATYR |
|---|---|---|
| Founded | 1970 | 2005 |
| Country | United States | United States |
| Employees | N/A | 58 |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.1M | 77.0M |
| IPO Year | 1996 | N/A |
| Metric | NTIC | ATYR |
|---|---|---|
| Price | $8.00 | $0.83 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $3.67 |
| AVG Volume (30 Days) | 12.2K | ★ 788.8K |
| Earning Date | 04-09-2026 | 05-01-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $84,234,474.00 | N/A |
| Revenue This Year | $12.49 | N/A |
| Revenue Next Year | $7.64 | N/A |
| P/E Ratio | $402.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.10 | $0.64 |
| 52 Week High | $10.03 | $7.29 |
| Indicator | NTIC | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 41.98 | 52.37 |
| Support Level | $7.91 | $0.68 |
| Resistance Level | $8.25 | $0.86 |
| Average True Range (ATR) | 0.18 | 0.05 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 16.67 | 67.67 |
Northern Technologies International Corp is a United States-based firm that develops and markets proprietary, environmentally beneficial products and services world wide either directly or through a network of joint ventures, distributors, and agents. It operates through two segments, which include ZERUST products and services and Nature-Tec products. Its main business is providing corrosion prevention solutions that are marketed under the ZERUST brand. The company also sells a portfolio of bio-based and biodegradable (compostable) polymer resin compounds and finished products marketed under the Nature-Tec brand. The ZERUST brand generates a vast majority of the revenue for the company. The company generates the majority of its revenue in the United States.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).